P15‐3: Potential amelioration of pulmonary hypertension in COPD by budesonide/glycopyrronium/formoterol via central NFκB inflammatory signaling deactivation: In vivo mouse model.

Recently, BGF (budesonide//glycopyrronium/formoterol) triple therapy showed benefit in improving lung function of COPD patients; however, whether COPD-PH prevention can also be achieved is unknown. B Methods b : We utilized intratracheal elastase-induced emphysema mouse model and performed experiments in three phases illustrating COPD progression: inflammatory (1 day post-elastase), emphysema (3 weeks post-elastase) and PH (4 weeks post-elastase). 1 Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Japan, 2 Lab... B Backgrounds and Aims b : COPD (Chronic Obstructive Pulmonary Disease) is a growing health problem causing mortality, partly due to pulmonary hypertension (PH) development. [Extracted from the article]